best peptides FAQ

Focus the protocol on BPC-157 and thymosin beta-4 rather than neurotropic peptides. Vascular-predominant Long COVID. Orthostatic intolerance, palpitations, poor perfusion. Responds to angiogenesis and endothelial repair mechanisms. BPC-157 restores nitric oxide signaling within 10–14 days in animal wound healing models, and TB-500 reduces inflammatory cytokines that perpetuate vascular inflammation. Combining both targets the problem from complementary angles: BPC-157 rebuilds vessel integrity while TB-500 clears the inflammatory environment preventing healing. Research dosing typically runs 12–16 weeks before assessing vascular function improvements.

Discard it immediately. Cloudiness indicates bacterial contamination or peptide aggregation. Either renders the compound unsafe or inactive. LL-37 should remain clear and colorless after reconstitution. If cloudiness develops within 24–48 hours, the bacteriostatic water was contaminated during mixing. If it develops after a week, the vial wasn't refrigerated properly. Do not inject cloudy peptide. Bacterial infection risk outweighs any potential immune benefit.

Switch to epithalon instead of increasing melatonin dose. Chronic exogenous melatonin (especially doses above 3mg nightly) suppresses endogenous pineal production through negative feedback. Your pineal gland produces less because you're supplementing externally. Epithalon restores your pineal gland's ability to produce melatonin on its own by activating telomerase in pineal cells and reducing calcification. The 10-day cycling protocol (10 days on, 20 days off) prevents receptor downregulation while allowing cumulative benefits to build over months.

Verify receptor expression first. Even MC1R-positive melanocyte lines can downregulate receptor density after extended passage in culture. Western blot for MC1R protein or qPCR for MC1R mRNA confirms functional receptor presence. If receptor expression is confirmed, test a positive control (forskolin at 10 µM) to verify that downstream cAMP signaling and tyrosinase activation pathways remain intact. Non-responsiveness despite functional MC1R suggests peptide degradation during reconstitution or storage. Mass spectrometry of the working solution identifies truncation or oxidation.

Target mitochondrial function with MOTS-c rather than continuing vascular or neurological peptides. Isolated fatigue post-recovery suggests the cellular energy machinery hasn't restored normal oxidative phosphorylation. MOTS-c directly activates AMPK, the enzyme that signals mitochondria to increase ATP production through fat oxidation instead of glycolysis. Research dosing uses 5–15 mg subcutaneous 2–3 times weekly. Exercise capacity improvements in metabolic studies appear at 6–8 weeks. Our team has seen this pattern frequently. Patients who cleared brain fog and vascular symptoms but plateau at 70% energy often have residual mitochondrial impairment that energy-focused peptides can address.

This indicates the rate-limiting factor isn't melatonin synthesis but downstream REM gating mechanisms. Possibly GABA-A receptor desensitisation or insufficient adenosine accumulation during wakefulness. Confirm melatonin elevation with salivary melatonin assays at 23:00 and 02:00. If levels are elevated but REM remains unchanged, the issue is sleep pressure insufficiency. Combine Epitalon with sleep restriction protocols (limiting time in bed to 6 hours for 3 nights) to increase homeostatic sleep pressure, then reassess REM percentage.

Melanotan II is the better choice at 0.5–1.0mg/kg subcutaneous. MC1R activation produces dose-dependent skin darkening that serves as a visual biomarker for receptor engagement, which simplifies dose-response tracking in rodent and primate models. PT-141 lacks this feature because of its MC4R selectivity.

Fragmented sleep. Waking 3–5 times per night even if you fall back asleep quickly. Indicates disrupted sleep-stage transitions, usually between NREM Stage 2 and Stage 3 or between REM cycles. DSIP stabilizes delta-wave patterns during slow-wave sleep, reducing microarousals that fragment deep sleep. Pinealon addresses circadian misalignment that causes mid-sleep awakenings by restoring pineal sensitivity to light-dark cues. Clinical trials show DSIP + pinealon combination reduces wake-after-sleep-onset (WASO) by 30–45% within four weeks.

Prioritize semax and selank over mitochondrial peptides. Brain fog without significant fatigue suggests the primary dysfunction is neuroinflammatory rather than metabolic. Semax crosses the blood-brain barrier and elevates BDNF. The molecule responsible for synaptic plasticity and memory consolidation. Selank reduces the inflammatory cytokines (IL-6, TNF-alpha) that impair hippocampal function. Russian research protocols use semax 300–600 mcg intranasal daily for 30–60 days, often paired with selank at the same dose for synergistic anti-inflammatory effects. Cognitive improvements typically emerge at week 4–6 as neuroplasticity mechanisms engage.

P21 at 1mg/kg subcutaneously daily supports dendritic spine formation over weeks, not hours. This isn't an acute intervention. It's structural remodeling that accumulates. Research from the University of Queensland used 28-day protocols to demonstrate spine density increases, meaning short-term studies won't capture the full effect.

Semax is the peptide of choice for BDNF-mediated neuroplasticity. Research dosing ranges from 600mcg to 1.5mg intranasally once or twice daily, with effects persisting 48–72 hours post-dose. Studies published in the Journal of Psychopharmacology found that 14-day Semax administration improved working memory performance under stress by 27% compared to baseline.

Continue the protocol for at least 10–14 days before evaluating efficacy. Semax operates through gene expression changes (BDNF upregulation), not acute neurotransmitter modulation. The mechanism requires 48–72 hours to produce measurable synaptic changes, and subjective cognitive improvements lag behind molecular markers by several days. Clinical trials measuring memory retention improvements used 14-day protocols for this reason.

Contact the supplier immediately and request potency verification or replacement. Any temperature excursion above 8°C for lyophilised peptides or above 4°C for reconstituted solutions compromises structural integrity. Peptides don't "go bad" in a way that's visually obvious. They denature at the molecular level, rendering them biologically inactive while appearing unchanged. If shipping took longer than 48 hours without cold packs, the compound is likely degraded.

Semax and Selank stack well because they operate through non-overlapping pathways. BDNF upregulation (Semax) and GABAergic stabilization (Selank) address different bottlenecks in cognitive performance. Standard stack protocol: Semax 600 mcg morning, Selank 750 mcg morning and afternoon. Run for 21 days, then cycle off for 7 days. Adding MOTS-c (5 mg subcutaneous twice weekly) enhances mitochondrial function but doesn't directly modulate neurotransmitter systems. The benefit is cumulative rather than synergistic.

Use Selank intranasally at research doses of 300–600mcg per administration. The GABAergic modulation produces anxiolytic effects within 20–30 minutes without the cognitive impairment or motor sedation associated with benzodiazepines. Research protocols show efficacy for 4–6 hours per dose. Twice-daily administration maintains effect without tolerance buildup.

Selank 750 mcg twice daily for 10–14 days before the high-demand period. The anxiolytic effect requires upfront loading. Single-dose administration won't produce meaningful results. GABAergic modulation stabilizes over 3–5 days, with peak cognitive benefit appearing around day 7. If anxiety is chronic rather than situational, this protocol works best as a 28-day cycle followed by a 7-day washout.

Use Semax 600 mcg intranasal 90 minutes before the task. BDNF upregulation peaks at 2–4 hours post-administration, aligning with the acute cognitive window. This isn't a stimulant. You won't feel a subjective 'kick'. But reaction time, verbal recall, and sustained attention improve measurably in that timeframe. Pair it with structured task prioritization to maximize the window.

Consult a prescribing physician before combining peptides with overlapping neuroplasticity mechanisms. The interaction effects are not well-studied, and combining BDNF upregulation (Semax) with exogenous neurotrophin delivery (Cerebrolysin) could theoretically over-activate synaptic remodelling pathways. No published studies document safety or efficacy of this combination. Sequential protocols (e.g., Cerebrolysin for 4 weeks followed by Semax maintenance) have been used clinically in post-stroke rehabilitation, but dosing must be physician-supervised.

Regulatory approval requires Phase III randomized controlled trials comparing new agents to established DMARDs like methotrexate. A 7–10 year process costing $500 million to $1 billion per compound. Peptides face additional manufacturing challenges: they degrade rapidly at room temperature, require cold-chain distribution, and lose potency if reconstituted incorrectly. Even with superior preclinical efficacy, commercialization barriers explain why peptide therapeutics rarely reach pharmacy shelves despite decades of promising research.

Administer anyway. The reparative phase extends through week 6, and peptides like TB-500 and GHK-Cu remain effective during callus formation and early remodelling. BPC-157's angiogenic effect is most pronounced in the inflammatory phase (days 1–7), but research shows continued benefit through week 3 when soft callus transitions to hard callus. Late administration won't recover the lost time, but it can still accelerate the remaining phases compared to unassisted healing.